Saturday 17 October 2026
Export RIGL’s income statement to Excel — free account
Rigel Pharmaceuticals, Inc.
RIGL Healthcare Biotechnology
Rigel Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $294.3 million, up 64.1% from fiscal 2024. In the quarter to June 2026, revenue fell 22.6%, EPS fell 72.1%, free cash flow fell 230.0% and total debt fell 66.6%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
45.97
1.28
−2.71%
Follow RIGL
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
2.12 | 17.52 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Piotroski F-Score |
6 | 7 | 4 | 1 | 7 | 4 | 3 | 4 | 3 | 1 |
Altman Z-Score |
2.71 | (8.66) | (14.88) | (13.39) | (7.80) | (11.28) | (10.46) | (5.05) | 1.37 | (15.04) |
P/S ratio |
2.62 | 1.65 | 2.17 | 1.90 | 3.03 | 5.44 | 6.04 | 8.13 | 44.49 | 11.53 |
Altman Z″-Score (non-manufacturers) |
0.31 | (23.75) | (37.95) | (33.96) | (22.50) | (37.01) | (28.03) | (22.75) | (24.48) | (43.26) |
P/FCF ratio |
10.21 | 9.45 | 0.00 | 0.00 | 86.04 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Beneish M-Score |
0.78 | (2.31) | (3.48) | 0.06 | (3.35) | (1.18) | 10.69 | — | — | — |
P/Operating CF |
35.05 | 20.39 | (40.71) | (10.43) | (23.67) | (37.93) | (37.13) | 31.71 | (25.37) | (18.86) |
P/B ratio |
1.97 | 89.93 | 0.00 | 0.00 | 14.87 | 17.36 | 6.66 | 3.36 | 4.97 | 4.27 |
Price to Tangible BV |
2.10 | 0.00 | 0.00 | 0.00 | 14.87 | 17.36 | 6.66 | 3.36 | 4.97 | 4.27 |
EV/Sales |
2.17 | 1.51 | 2.13 | 1.74 | 2.32 | 5.09 | 4.55 | 5.31 | 34.22 | 7.87 |
EV/EBITDA |
5.03 | 10.53 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
8.43 | 8.60 | (43.44) | (2.84) | 58.99 | (10.60) | (6.50) | (4.10) | (4.96) | (2.11) |
EV/FCF |
8.45 | 8.65 | (12.18) | (2.86) | 66.04 | (10.35) | (6.28) | (4.02) | (5.00) | (2.10) |
Quick Ratio |
2.08 | 1.88 | 1.64 | 1.51 | 2.21 | 1.79 | 1.86 | 4.78 | 6.31 | 3.31 |
Current Ratio |
2.42 | 2.13 | 1.86 | 1.78 | 2.43 | 2.18 | 2.04 | 4.94 | 6.40 | 3.37 |
Net Debt/EBITDA |
(1.05) | (0.97) | 0.23 | 0.34 | 9.51 | 1.32 | 1.27 | 1.76 | 1.46 | 1.09 |
Debt/Assets |
4.38% | 31.96% | 44.68% | 29.38% | 11.90% | 17.95% | 6.65% | 0.00% | 0.00% | 0.30% |
Debt/Equity |
0.06 | 15.94 | (1.83) | (2.90) | 0.66 | 0.58 | 0.18 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.87 | 1.28 | 0.93 | 0.80 | 1.07 | 0.84 | 0.41 | 0.34 | 0.05 | 0.19 |
Operating CF/Net income |
0.21 | 1.80 | 0.23 | 1.26 | (0.33) | 1.75 | 0.62 | 0.83 | 0.99 | 1.10 |
Capex/Depreciation |
0.00 | (0.20) | (19.42) | 0.47 | (0.43) | (2.16) | 3.73 | 6.43 | 4.94 | (0.68) |
Interest Coverage |
17.14 | 3.06 | (2.98) | (14.99) | (2.57) | (21.41) | (206.24) | — | — | (159.59) |
| 185.94% | (137.92%) | 118.75% | (699.05%) | (55.63%) | (67.72%) | (81.73%) | (66.96%) | (100.20%) | (94.55%) | |
| 108.34% | 12.44% | (19.95%) | (38.84%) | (12.90%) | (23.06%) | (46.67%) | (54.59%) | (79.08%) | (65.96%) | |
ROIC |
30.28% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
260.43% | 24.32% | (54.35%) | (113.63%) | (19.24%) | (58.53%) | (106.26%) | (63.70%) | (78.01%) | (126.35%) |
Average Days of Receivables |
64.20 | 84.73 | 95.40 | 122.39 | 37.84 | 53.67 | 62.25 | 33.43 | 0.00 | 0.00 |
Research and Development Expense of Revenue |
11.31% | 13.04% | 20.98% | 50.13% | 43.71% | 55.33% | 89.20% | 105.38% | 1,031.87% | 311.27% |
Selling, General and Administrative Expense of Revenue |
39.38% | 63.06% | 90.47% | 93.52% | 61.57% | 70.52% | 125.81% | 157.28% | 843.69% | 102.58% |
Intangible Assets out of Total Assets |
0.05 | 0.17 | 0.12 | 0.11 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
4.32% | 6.91% | 7.53% | 10.30% | 6.36% | 6.72% | 15.37% | 17.31% | 133.52% | 35.98% |
Graham Net Nets |
0.15 | (0.09) | (0.18) | (0.14) | 0.04 | 0.02 | 0.07 | 0.29 | 0.20 | 0.23 |
Graham Number |
99.56 | 2.01 | 7.34 | 7.82 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
47.26% | 5.71% | (9.97%) | (25.37%) | (3.77%) | (4.57%) | (18.69%) | (19.57%) | (15.40%) | (29.72%) |
Free Cash Flow Yield |
9.79% | 10.59% | (8.06%) | (32.09%) | 1.16% | (9.05%) | (11.99%) | (16.23%) | (15.39%) | (32.59%) |
Revenue per Share |
16.36 | 10.20 | 6.72 | 7.05 | 8.75 | 6.44 | 3.54 | 2.77 | 0.36 | 2.16 |
Operating CF per Share |
4.21 | 1.79 | (0.33) | (4.33) | 0.34 | (3.09) | (2.48) | (3.66) | (6.14) | (8.04) |
Capex per Share |
0.00 | (0.02) | (0.85) | 0.03 | (0.04) | (0.07) | (0.09) | (0.07) | 0.05 | (0.08) |
Free Cash Flow per Share |
4.21 | 1.77 | (1.18) | (4.30) | 0.31 | (3.17) | (2.57) | (3.73) | (6.09) | (8.12) |
Cash per Share |
8.61 | 4.40 | 3.27 | 3.41 | 7.33 | 3.40 | 5.86 | 8.01 | 9.16 | 7.92 |
Shareholders Equity per Share |
21.76 | 0.19 | (1.65) | (0.80) | 1.78 | 2.02 | 3.21 | 6.84 | 7.97 | 5.83 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
21.76 | 0.19 | (1.65) | (0.80) | 1.78 | 2.02 | 3.21 | 6.84 | 7.97 | 5.83 |
Free Cash Flow |
75.66 | 31.17 | (20.48) | (73.31) | 5.25 | (53.45) | (42.96) | (59.93) | (76.99) | (76.60) |
Working Capital |
140.93 | 71.80 | 46.00 | 50.69 | 90.91 | 48.14 | 60.79 | 109.25 | 99.10 | 53.63 |
Capital Expenditures |
— | (0.30) | (14.74) | 0.44 | (0.63) | (1.26) | (1.45) | (1.11) | 0.57 | (0.72) |
Net Current Asset Value |
118.05 | (25.58) | (46.60) | (31.99) | 17.51 | 12.63 | 25.25 | 107.76 | 98.97 | 53.11 |
EV/EBIT |
5.08 | 11.19 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
0.00 | 0.00 | 0.13 | 0.00 | 0.00 | 0.01 | 0.02 | 0.02 | (0.13) | 0.04 |
Price to Operating Income |
6.14 | 12.22 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.00 | 16.51 | 4.60 | 1.09 | 0.66 | 0.22 | (0.18) | (0.12) | 0.13 | 0.91 |
Cash ROIC |
13.30% | 23.44% | (25.39%) | (87.24%) | 3.00% | (48.08%) | (26.57%) | (25.14%) | (35.58%) | (58.91%) |
Accounts Receivable Turnover |
6.30 | 4.97 | 3.30 | 4.31 | 9.49 | 8.33 | 8.36 | 20.80 | 0.00 | 0.00 |
Accounts Payable Turnover |
3.73 | 3.56 | 0.48 | 0.13 | 0.29 | 0.23 | 0.17 | 0.06 | 0.00 | 0.00 |
Inventory Turnover |
2.24 | 3.24 | 0.97 | 0.22 | 0.26 | 0.60 | 0.81 | 0.26 | — | — |
Average Days of Payables |
133.77 | 65.36 | 366.64 | 4,697.21 | 1,279.02 | 1,511.79 | 1,672.72 | 8,127.93 | 0.00 | 0.00 |
Days of Inventory on Hand |
214.04 | 117.48 | 283.48 | 1,902.84 | 2,229.77 | 668.01 | 545.49 | 1,136.97 | — | — |
Average Receivables |
46.69 | 36.08 | 35.44 | 27.90 | 15.72 | 13.04 | 7.09 | 2.14 | — | — |
Average Payables |
5.27 | 5.24 | 14.83 | 13.15 | 3.75 | 3.93 | 5.27 | 4.51 | 4.10 | 4.16 |
Average Inventory |
8.75 | 5.76 | 7.32 | 7.87 | 4.13 | 1.50 | 1.12 | 1.12 | — | — |
Average Assets |
338.79 | 140.60 | 125.75 | 150.80 | 138.85 | 128.97 | 143.34 | 129.11 | 98.62 | 104.94 |
Average Common Equity |
197.38 | (12.68) | (21.13) | 8.38 | 32.20 | 43.92 | 81.85 | 105.26 | 77.84 | 73.20 |
Columns are period end dates